Clinical Trials Logo

Digestive System Neoplasm clinical trials

View clinical trials related to Digestive System Neoplasm.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05160168 Terminated - Neoplasms Clinical Trials

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Start date: January 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

NCT ID: NCT03724071 Terminated - Colorectal Neoplasm Clinical Trials

Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Start date: October 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will include two parts: - In the phase I part: safety will be assessed in consecutive cohorts of 3 to 6 patients at increasing doses of TG6002 in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors. - In the phase IIa part: evaluation of efficacy and further evaluation of safety of multiple administrations of TG6002 in combination with flucytosine (5-FC) in patients with colorectal cancer and liver metastases. In both parts, tumor response will be evaluated on local assessment using RECIST 1.1. All patients will be followed up until disease progression or death due to any cause or the date of data cut-off, whichever occurs first.

NCT ID: NCT02602067 Terminated - Clinical trials for Lymphoma, Non-Hodgkin

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Tenatumomab
Start date: November 2015
Phase: Phase 1
Study type: Interventional

Tenatumomab is a Sigma-Tau developed new anti-Tenascin antibody. It is a murine monoclonal antibody directed towards Tenascin-C. By means of this antibody, Tenascin-C expression was studied on a commercial tissue array slides each carrying malignant breast, colorectal, lung, ovarian or B and T cell Non-Hodgkin Limphoma tissue sections. All these cancers type showed positivity to Tenascin-C between the 64% and 13.3%. Consequently, Sigma-tau is exploring the use of the 131I-labeled Tenatumomab for anti-cancer radioimmunotherapy.

NCT ID: NCT01939210 Terminated - Depression Clinical Trials

Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy

Start date: February 2010
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies the effects of meditation-based breathing training on patients' control of their breathing patterns and breathing-related movement, as well as on their psychological distress and treatment experience during radiation therapy. Meditation-based breathing training may decrease breathing-related movement and the amount of stress by improving breathing patterns in patients with abdominal or lung cancer undergoing radiation therapy.